Levodopa/carbidopa (ND0612) vs Rytary (IPX066)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Levodopa/carbidopa (ND0612) · Onerji

Marketed by NeuroDerm Ltd.

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT02577523 · Phase 2 · completed

Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.

Reported efficacy

Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)

Result source: NCT02577523

Rytary (IPX066)

Marketed by Amneal Pharmaceuticals

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT00974974 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).

Reported efficacy

Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)

Result source: NCT00974974

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLevodopa/​carbidopa (ND0612)Rytary (IPX066)
OFF time, change-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505—Not reported
ON time without troublesome dyskinesia, change—Trial running · NCT04006210—Not reported
UPDRS Part III, change—Trial running · NCT0400621021.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791
MDS-UPDRS Part II, change—Trial running · NCT04006210—Not reported

OFF time, change

Levodopa/​carbidopa (ND0612)
-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505
Rytary (IPX066)
—Not reported

ON time without troublesome dyskinesia, change

Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210
Rytary (IPX066)
—Not reported

UPDRS Part III, change

Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210
Rytary (IPX066)
21.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791

MDS-UPDRS Part II, change

Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210
Rytary (IPX066)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Levodopa/carbidopa (ND0612): 4 of 5 rows · Rytary (IPX066): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevodopa/​carbidopa (ND0612)Rytary (IPX066)
PDQ-39
absolute change · score
-6.6 vs -1.8 placebo score @ 2wka,b,c,d
NCT01883505 · Phase 2 · registry result, not featured evidence
-6 vs 0.6 placebo score @ 30wk390 mg LDe,a,b,c,d
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more doses
-3.8 vs 0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-4.4 vs 0.6 placebo score @ 30wk145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
Dropout rate
—24-hr Infusionf
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
0%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
—g
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
24.5%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
20.2%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
17.2%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
8.1%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—24-hr Infusionf
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
—Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
—g
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
15.3%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
14.4%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
5.7%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
2.6%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Serious AEs
10.5%24-hr Infusionf
NCT02577523 · Phase 2
show 4 more results
10.5%14-hr Infusion
NCT02577523 · Phase 2
5.3%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
5.5%g
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
2%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.8%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.6%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
2.3%Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
15.6%Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
25%Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
1.1%
NCT01130493 · Phase 3 · registry result, not featured evidence
7%
NCT01096186 · Phase 3 · registry result, not featured evidence
0%
NCT00869791 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
24-hr Infusionf
infusion site nodule 57.9%
infusion site erythema 26.3%
infusion site bruising 21.1%
NCT02577523 · Phase 2
show 4 more results
14-hr Infusion
infusion site nodule 36.8%
infusion site bruising 15.8%
infusion site haemorrhage 15.8%
NCT02577523 · Phase 2
fatigue 10.5% (placebo 0%)
headache 10.5% (placebo 9.1%)
abdominal pain lower 5.3% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
blood creatinine abnormal 12.5% (placebo 0%)
dental caries 12.5% (placebo 0%)
diarrhoea 12.5% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
back pain 12.5% (placebo 0%)
pain in extremity 12.5% (placebo 9.1%)
abdominal pain lower 0% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
g
insomnia 3.5%
fall 3%
nausea 3%
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
390 mg LD
nausea 20.4% (placebo 8.7%)
headache 17.3% (placebo 10.9%)
dizziness 12.2% (placebo 5.4%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
245 mg LD
dizziness 19.2% (placebo 5.4%)
nausea 19.2% (placebo 8.7%)
headache 12.5% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
145 mg LD
nausea 13.8% (placebo 8.7%)
dizziness 9.2% (placebo 5.4%)
headache 6.9% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
nausea 11.6%
dyskinesia 7%
fall 7%
NCT01411137 · Phase 3 · registry result, not featured evidence
upper respiratory infection 15.6%
anxiety 6.3%
fall 6.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
fall 16.7%
orthostatic hypotension 16.7%
anxiety 8.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
dyskinesia 4.5%
confusional state 3.4%
insomnia 3.4%
NCT01130493 · Phase 3 · registry result, not featured evidence
insomnia 5.8%
dyskinesia 5.5%
fall 5.3%
NCT01096186 · Phase 3 · registry result, not featured evidence
anxiety 3.7%
fatigue 3.7%
feeling of warth in abdomen 3.7%
NCT00869791 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 30 weeks versus 2 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Levodopa/carbidopa (ND0612)

OFF Time -2.8 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.3 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
Good ON" Time 3.7 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
2.8 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 3 Motor -19.1 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-10.7 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 2 ADL -2.9 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.9 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
CGI-I 52.6% (n=19) @ 0.43wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 10 Participants as posted
show 1 more result
47.4% (n=19) @ 0.43wk*14-hr Infusion
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 9 Participants as posted
CGI-I 73.7% (n=19) @ 4wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 14 Participants as posted
show 1 more result
68.4% (n=19) @ 4wk*14-hr Infusion
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 13 Participants as posted
PDSS-2 -4.1 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-0.8 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
PDQ-39 Summary Index -7.5 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-3.7 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
OFF Time -2.1 vs -1.4 placebo hours @ 2wk
absolute change · hours
NCT01883505 · Phase 2 · registry result, not featured evidence
UPDRS Total -11.7 vs -9.3 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDSS -17.1 vs -0.5 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
CGIC 89.5% (n=19) vs 36.4% (n=11) placebo @ 2wk
event count · % of participants
Improved
NCT01883505 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted

Rytary (IPX066)

Off" Time 23.82% (n=201) vs 29.79% (n=192) IR CD-LD @ 22wk
absolute value · percentage points
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
Off" Time 3.87 vs 4.88 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
3.82 vs 5.22 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
3.83 vs 5.83 IR CD-LD hours @ 1wk
NCT00869791 · Phase 2 · registry result, not featured evidence
On" Time Without Troublesome Dyskinesia 11.84 vs 10.91 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 1 more result
11.36 vs 9.98 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS II III Sum -14.9 vs -0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-12.9 vs -0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-11.7 vs -0.6 placebo score @ 30wk145mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PGIC 5.2 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.4 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.3 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
CGI-C 5.5 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.7 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.6 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
PDQ-8 9.6 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 3 more results
8.1 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
8.5 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
9 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
Awake OFF Time 23.98% (n=83) vs 32.48% (n=83) CLE @ 2wk
absolute value · percentage points
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 29.3 vs 31.7 CLE score @ 2wk
absolute change · score
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 26.4 score @ 39wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence
UPDRS Total 30.5 score @ 39wk
absolute value · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence
PGI-I 5.4 score @ 39wk
absolute value · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa/carbidopa (ND0612)'s landscape · Rytary (IPX066)'s landscape